Overexpression of DEK gene is correlated with poor prognosis in hepatocellular carcinoma
Authors:
Open Access
- 27 October 2014
- journal article
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 11 (2) , 1318-1323
Abstract
The oncogene DEK was originally identified as one of the parts of the DEK‑CAN fusion gene, arising from the translocation (6;9) in a subtype of acute myeloid leukemia. Since then, DEK has been shown to promote tumorigenesis in a variety of cancer cell types through its roles in inhibiting cell differentiation, senescence and apoptosis. Certain studies have established that DEK is dysregulated in several types of cancer, including hepatocellular carcinoma (HCC). However, its clinical significance in human HCC remains unknown. In this study, the expression of DEK mRNA and protein was examined in 55 surgical HCC specimens and matched non‑tumorous tissues. In addition, the correlation between DEK expression and clinicopathological characteristics and prognosis was analyzed. mRNA and protein levels of DEK were found to be significantly overexpressed in the majority of HCC tumors when compared with matched normal hepatic tissues (P<0.05). In addition, the expression pattern of DEK was closely correlated with differentiation status, portal venous invasion and tumor size (P<0.05). Kaplan‑Meier curves demonstrated that patients with higher DEK expression levels had significantly poorer survival than those with lower DEK expression levels (P=0.003). In addition, Cox regression analysis demonstrated that the level of DEK expression may be a valuable prognostic factor (P<0.05). These results suggested that DEK may play a significant role in hepatocyte differentiation and may serve as a useful prognostic marker and biomarker for the staging of HCC.Keywords
This publication has 24 references indexed in Scilit:
- DEK expression in melanocytic lesionsHuman Pathology, 2011
- Oncoprotein DEK as a tissue and urinary biomarker for bladder cancerBMC Cancer, 2011
- Melanoma Proliferation and Chemoresistance Controlled by the DEK OncogeneCancer Research, 2009
- Pathology of early hepatocellular carcinomaHepatology Research, 2007
- Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigenBMC Immunology, 2007
- DEK Expression is Controlled by E2F and Deregulated in Diverse Tumor TypeCell Cycle, 2006
- Expression and significance of tumor-related genes in HCCWorld Journal of Gastroenterology, 2005
- Risk Factors, Prevention, and Management of Postoperative Recurrence After Resection of Hepatocellular CarcinomaAnnals of Surgery, 2000
- Mortality by cause for eight regions of the world: Global Burden of Disease StudyThe Lancet, 1997
- The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.Molecular and Cellular Biology, 1992